IPLEDGE program

Uses your system voice; voice and rate in settings.

Snapshot

≈ 4 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

The iPLEDGE program is a program by the U.S. Food and Drug Administration (FDA) intended to manage the risk of birth defects caused by isotretinoin, a prescription medication used for the treatment of acne. Patients, their doctors and their pharmacists are required by the FDA to register and use the iPLEDGE web site in order to receive, prescribe or dispense isotretinoin. Isotretinoin carries a high risk of causing severe birth defects if taken during pregnancy (see Teratogenicity of isotretinoin) and the goals of the iPLEDGE REMS (risk evaluation and mitigation strategy) program are to prevent fetal exposure to isotretinoin and to inform prescribers, pharmacists, and patients about isotretinoin's serious risks and safe-use conditions. The iPLEDGE program was put into place by a group formed by the companies that manufactured the drug at the time called the Isotretinoin Products Manufacturing Group (IPMG) under the direction of the Food and Drug Administration. The program launched on March 1, 2006, at the beginning of the annual meeting of the American Academy of Dermatology. According to a study published in 20111, the program has not significantly reduced exposure of pregnant people to the drug in comparison to the previous SMART program. It has been criticized for being overly complicated and difficult for prescribers, pharmacists and patients to navigate successfully.

The iPLEDGE program is a program by the U.S. Food and Drug Administration (FDA) intended to manage the risk of birth defects caused by isotretinoin, a prescription medication used for the treatment of acne. Patients, their doctors and their pharmacists are required by the FDA to register and use the iPLEDGE web site in order to receive, prescribe or dispense isotretinoin. Isotretinoin carries a high risk of causing severe birth defects if taken during pregnancy (see Teratogenicity of isotretinoin) and the goals of the iPLEDGE REMS (risk evaluation and mitigation strategy) program are to prevent fetal exposure to isotretinoin and to inform prescribers, pharmacists, and patients about isotretinoin's serious risks and safe-use conditions. The iPLEDGE program was put into place by a group formed by the companies that manufactured the drug at the time called the Isotretinoin Products Manufacturing Group (IPMG) under the direction of the Food and Drug Administration. The program launched on March 1, 2006, at the beginning of the annual meeting of the American Academy of Dermatology. According to a study published in 2011, the program has not significantly reduced exposure of pregnant people to the drug in comparison to the previous SMART program. It has been criticized for being overly complicated and difficult for prescribers, pharmacists and patients to navigate successfully. AAD's 12/13/2021 statement

Text derived from https://en.wikipedia.org/w/index.php?oldid=1376128184 under CC BY-SA 4.0; modifications have been made.

References

  1. ↩Wikipedia “IPLEDGE program” revision 1376128184 · retrieved 2026-10-20 publication date (×1) · confidence 0.95 revision URL